The Kidney Foundation of Canada

Dr.  Ioan-Andrei Iliuta 

Dr. Ioan-Andrei Iliuta

University Health Network, Ontario/Can-Solve CKD KRESCENT Trainee
Supervisor(s):  Dr. York Pei, Dr. James W. Scholey
Partnership with: Otsuka Pharmaceuticals Canada and the PKD Foundation of Canada

Modulating dysfunctional metabolic pathways to slow disease progression autosomal dominant polycystic kidney disease


2017-2020:  $195,000  |  KRESCENT Post-Doctoral Fellowships |  Category: Genetics

Biography

After having received his medical degree at Laval University in 2010, Dr Iliuta completed residency training in internal medicine (2010-2013) and nephrology (2013-2015) in Quebec City. He then pursued a fellowship in Hereditary Kidney Disease under the supervision of Dr York Pei at Toronto General Hospital, University Health Network, while undergoing graduate training in the Translational Research Program at the Institute of Medical Science, University of Toronto. His clinical interests range from autosomal dominant polycystic kidney disease to tuberous sclerosis complex and inherited tubulopathies. His current research focuses on investigating novel disease-modifying therapies for the treatment of polycystic kidney disease. In the fall, he will be starting a PhD in Biomedical Science at the University of Toronto, with a focus on the therapeutics of AMP kinase in polycystic kidney disease.

Lay Summary

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited form of kidney disease manifesting in adults, in which numerous cysts enlarge progressively until they cause severe kidney failure requiring dialysis or a transplant. Although ADPKD is a major cause of kidney failure in North America, effective treatments to slow disease progression are lacking. By acting on specific pathways involved in the metabolism (specifically, energy sensing and production) of cyst cells in APDKD, either through drug combinations or dietary changes, we hope to attenuate the severity of renal disease: this would result in smaller kidneys, better quality of life, and a longer interval to kidney failure.